Gedeon Richter says its attempts to secure a European marketing authorization for biosimilar pegfilgrastim have demonstrated that the highest-quality biosimilars must be supported by a data package of equal quality if they are to make it through the approval process.
The Hungarian firm’s management made the observation as Richter announced that it will take “another two years” for itself and...






